Isabelle Dussault
Overview
Explore the profile of Isabelle Dussault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
930
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spira A, Awada A, Isambert N, Lorente D, Penel N, Zhang Y, et al.
Front Oncol
. 2022 Dec;
12:981940.
PMID: 36568239
Background: We report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβRII (a TGF-β...
2.
Gulley J, Schlom J, Barcellos-Hoff M, Wang X, Seoane J, Audhuy F, et al.
Mol Oncol
. 2021 Dec;
16(11):2117-2134.
PMID: 34854206
Transforming growth factor-β (TGF-β) and programmed death ligand 1 (PD-L1) initiate signaling pathways with complementary, nonredundant immunosuppressive functions in the tumor microenvironment (TME). In the TME, dysregulated TGF-β signaling suppresses...
3.
Reutershan M, Machacek M, Altman M, Bogen S, Cai M, Cammarano C, et al.
J Med Chem
. 2021 Oct;
64(21):16213-16241.
PMID: 34714078
Identification of low-dose, low-molecular-weight, drug-like inhibitors of protein-protein interactions (PPIs) is a challenging area of research. Despite the challenges, the therapeutic potential of PPI inhibition has driven significant efforts toward...
4.
Khasraw M, Weller M, Lorente D, Kolibaba K, Lee C, Gedye C, et al.
Neurooncol Adv
. 2021 May;
3(1):vdab058.
PMID: 34056607
Background: For patients with recurrent glioblastoma (rGBM), there are few options following treatment failure with radiotherapy plus temozolomide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular...
5.
Tan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, et al.
Target Oncol
. 2021 May;
16(4):435-446.
PMID: 34009501
Background: Esophageal adenocarcinoma patients have limited treatment options. TGF-β can be upregulated in esophageal adenocarcinoma, and blocking this pathway may enhance clinical response to PD-(L)1 inhibitors. Bintrafusp alfa is a...
6.
Lin C, Doi T, Muro K, Hou M, Esaki T, Hara H, et al.
Target Oncol
. 2021 Apr;
16(4):447-459.
PMID: 33840050
Background: Patients with esophageal squamous cell carcinoma (SCC) have limited treatment options. Blocking transforming growth factor-β (TGFβ), which can be overexpressed in these tumors, may enhance responses to programmed cell...
7.
Yoo C, Oh D, Choi H, Kudo M, Ueno M, Kondo S, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32461347
Background: Patients with biliary tract cancer (BTC) have poor prognosis with few treatment options. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth...
8.
Kang Y, Bang Y, Kondo S, Chung H, Muro K, Dussault I, et al.
Clin Cancer Res
. 2020 Apr;
26(13):3202-3210.
PMID: 32299818
Purpose: Patients with advanced gastric/gastroesophageal junction cancer (GC/GEJC) have limited treatment options after first-line therapy. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the...
9.
Paz-Ares L, Kim T, Vicente D, Felip E, Lee D, Lee K, et al.
J Thorac Oncol
. 2020 Mar;
15(7):1210-1222.
PMID: 32173464
Introduction: The safety and efficacy of bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β "trap")...
10.
Vugmeyster Y, Wilkins J, Koenig A, El Bawab S, Dussault I, Ojalvo L, et al.
Clin Pharmacol Ther
. 2020 Jan;
108(3):566-574.
PMID: 31955412
Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the TGF-βRII receptor (TGF-β "trap") fused to a human IgG1-blocking PD-L1, showed a manageable safety profile and...